Title:
USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING RHEUMATOID ARTHRITIS
Document Type and Number:
WIPO Patent Application WO/2020/203610
Kind Code:
A1
Abstract:
Provided is a medicinal drug for treating or preventing rheumatoid arthritis. As a medicinal drug for treating or preventing rheumatoid arthritis, the present invention uses, as an active ingredient, a compound that has an effect of blocking the T-type calcium channel (Cav3.2 channel) and that is represented by any one of general formulae (I)-(VI), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof.
More Like This:
| JP2013136597 | CYCLOSPORINE ANALOGUE MIXTURES AND THEIR USE AS IMMUNOMODULATING AGENTS |
| JP2005194246 | NF-κB ACTIVATION INHIBITOR |
| JP2002080368 | ANTIINFLAMMATORY AGENT |
Inventors:
GERALD W ZAMPONI (CA)
VINICIUS DE MARIA GADOTTI (CA)
KAWABATA ATSUFUMI (JP)
OGAWA TORU (JP)
TANAKA HIROTO (JP)
OOI ISAO (JP)
SAITO DAISUKE (JP)
HAYASHIDA KOHEI (JP)
YAMAMOTO KOHEI (JP)
VINICIUS DE MARIA GADOTTI (CA)
KAWABATA ATSUFUMI (JP)
OGAWA TORU (JP)
TANAKA HIROTO (JP)
OOI ISAO (JP)
SAITO DAISUKE (JP)
HAYASHIDA KOHEI (JP)
YAMAMOTO KOHEI (JP)
Application Number:
PCT/JP2020/013543
Publication Date:
October 08, 2020
Filing Date:
March 26, 2020
Export Citation:
Assignee:
NIPPON CHEMIPHAR CO (JP)
UTI LP (CA)
UNIV KINKI (JP)
UTI LP (CA)
UNIV KINKI (JP)
International Classes:
A61P19/02; A61K31/397; A61K31/402; A61K31/4025; A61K31/4184; A61K31/422; A61K31/427; A61K31/4355; A61K31/437; A61K31/4439; A61K31/444; A61K31/454; A61K31/4545; A61K31/4709; A61K31/496; A61K31/497; A61K31/501; A61K31/506; A61K31/517; A61K31/5377; A61K31/5386; A61K31/541; A61K31/695; A61P29/00; A61P43/00; C07D205/04; C07D207/14; C07D401/04; C07D401/12; C07D401/14; C07D403/04; C07D403/12; C07D403/14; C07D409/04; C07D413/04; C07D413/14; C07D417/04; C07D417/14; C07D471/04; C07D491/08; C07D491/107; C07D491/113; C07D498/08; C07F7/12
Domestic Patent References:
| WO2011058932A1 | 2011-05-19 | |||
| WO2017223474A1 | 2017-12-28 | |||
| WO2009131196A1 | 2009-10-29 | |||
| WO2015057655A1 | 2015-04-23 | |||
| WO2005095327A1 | 2005-10-13 | |||
| WO2020017569A1 | 2020-01-23 | |||
| WO2020025517A1 | 2020-02-06 | |||
| WO2019133635A1 | 2019-07-04 | |||
| WO2019133632A1 | 2019-07-04 |
Foreign References:
| JP2014505037A | 2014-02-27 | |||
| JP2018537501A | 2018-12-20 | |||
| CN105837577A | 2016-08-10 | |||
| JP2008543762A | 2008-12-04 | |||
| CN107556318A | 2018-01-09 | |||
| JP2016525562A | 2016-08-25 | |||
| JP2008509910A | 2008-04-03 | |||
| JP2002088073A | 2002-03-27 | |||
| JPS5515495A | 1980-02-02 |
Other References:
LEPRI, S. ET AL.: "Structure-metabolism relationships in human-AOX: Chemica insights from a large database of aza-aromatic and amide compounds", PNAS, vol. 114, no. 16, 3 April 2017 (2017-04-03), pages E3178 - E3187, XP055689694, DOI: 10.1073/pnas.1618881114
Attorney, Agent or Firm:
CHIGUSA Shinichi et al. (JP)
Download PDF: